Lamisil Once (Terbinafine)

Terbinafine inhibits the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Blocking this step leads to toxic squalene buildup and loss of membrane integrity, ultimately killing the fungus.

The prescribed dose and duration are determined by a qualified healthcare professional based on the type and severity of the infection. Patients should follow the prescriber’s instructions and not alter the amount or frequency of application without medical advice.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil Once (terbinafine) belongs to the allylamine class, which directly inhibits squalene epoxidase. This mechanism differs from azole antifungals that block lanosterol 14α‑demethylase. Allylamines often achieve faster fungal clearance and have a lower risk of drug‑enzyme interactions compared with many azoles.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Apply a thin layer of the cream or gel to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until it disappears, and wash your hands after each application unless the hands are the treatment site.

Although rare, serious adverse reactions can include severe allergic responses such as angioedema, anaphylaxis, or extensive contact dermatitis. If you experience swelling of the face, throat, difficulty breathing, or widespread rash, discontinue use immediately and seek emergency medical care.

Individuals with known hypersensitivity to terbinafine, other allylamines, or any component of the formulation should avoid using Lamisil Once. It should also be avoided on severely damaged, inflamed or infected skin unless specifically instructed by a healthcare professional.